Enanta Pharma (ENTA) Tops Q1 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Enanta Pharmaceuticals (ENTA) PT Raised to $82 at Baird
February 8, 2018 6:43 AM ESTBaird raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $82.00 (from $46.00) while maintaining a Neutral rating on strong Hep C royalties/pipeline progress.
... MoreJPMorgan Downgrades Enanta Pharmaceuticals (ENTA) to Neutral
February 8, 2018 4:40 AM ESTJPMorgan downgraded Enanta Pharmaceuticals (NASDAQ: ENTA) from Overweight to Neutral with a price target of $95.00 (from $55.00).
Analyst Jessica Fye steps to the sideline following the strong upside move noting the improvement in HCV royalties and lower tax rate in the US as... More
